1075.87USD+1.02%Mkt Cap: 955.08B USDP/E: 38.09Last update: 2026-05-26
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, incl…
Industry Peers
Drug Manufacturers - GeneralIndicators:|
Key Statistics
Company
Market Cap955.08B USD
Enterprise Value966.97B USD
Revenue (TTM)72.25B USD
Gross Profit54.13B USD
Net Income (TTM)20.64B USD
Revenue/Share80.61 USD
Last Price1075.87 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees50.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS5324571083
Valuation
P/E (Trailing)38.09
P/E (Forward)23.44
PEG1.37
EV/EBITDA26.70
EV/Revenue13.38
P/S12.86
P/B29.83
EPS (TTM)28.12
EPS (Forward)44.44
52W Range
623.7889% of range1133.95
52W High1133.95 USD
52W Low623.78 USD
Profitability
Gross Margin83.04%
Oper. Margin49.39%
EBITDA Margin50.13%
Profit Margin31.67%
ROE77.78%
ROA18.35%
Growth
Revenue Growth55.50%
Earnings Growth169.90%
Cash Flow & Leverage
Operating CF16.81B USD
CapEx (TTM)10.85B USD
FCF Margin12.67%
FCF Yield0.96%
Net Debt38.09B USD
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity1.60
Current Ratio1.50
Quick Ratio0.72
Book Value/Sh34.92 USD
Cash/Share5.923 USD
Dividends
Fwd Div Rate6.920 USD
Trail. Div Rate6.230 USD
Div. Yield0.66%
5Y Avg Yield0.91%
Payout Ratio22.13%
Ex-Div DateMay 15, 2026
Pay DateJun 10, 2026
Splits
Last Split2:1
Split DateOct 16, 1997
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)1210.00 USD
Target Range850.00 USD – 1500.00 USD
# Analysts29
Ownership
Shares Out.891.74M
Float889.33M
Insiders0.16%
Institutions85.52%
Short Interest
Short Ratio2.5d
Short % Float0.88%
Short % Out.0.88%
Shares Short7.86M
Short (prev mo.)7.70M
Technical
SMA 50941.58 (+14.3%)
SMA 200926.66 (+16.1%)
Beta0.48
S&P 52W Chg28.31%
Avg Vol (30d)3.29M
Avg Vol (10d)2.97M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—